599 related articles for article (PubMed ID: 31264261)
1. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
2. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
3. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
[TBL] [Abstract][Full Text] [Related]
4. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
6. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
7. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
11. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.
García-López S; Bocos JM; Gisbert JP; Bajador E; Chaparro M; Castaño C; García-Erce JA; Gomollón F
Blood Transfus; 2016 May; 14(2):199-205. PubMed ID: 27177405
[TBL] [Abstract][Full Text] [Related]
13. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
[TBL] [Abstract][Full Text] [Related]
14. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
[TBL] [Abstract][Full Text] [Related]
17. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
[TBL] [Abstract][Full Text] [Related]
18. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
19. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
[TBL] [Abstract][Full Text] [Related]
20. Ferric Carboxymaltose: A Review in Iron Deficiency.
Scott LJ
Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]